SAB Biotherapeutics (SABS) Payables (2020 - 2026)

SAB Biotherapeutics has reported Payables for 7 years, with the latest figure at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 102.58% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.4 million (up 102.58% YoY), and the FY2025 full-year result was $3.1 million, down 45.28% from the prior year.
• Payables for Q1 2026 stood at $5.4 million, up from $3.1 million in the prior quarter.
• The five-year high for Payables was $10.7 million in Q4 2022, with the low at $1.3 million in Q3 2024.
• Historically, Payables has averaged $4.5 million across 5 years, with a median of $3.1 million in 2025.
• Annual changes were most pronounced in 2023 — Payables slumped 84.17% — and 2024, when it soared 274.08%.
• SAB Biotherapeutics' Payables stood at $10.7 million in 2022, then decreased by 27.57% to $7.7 million in 2023, then decreased by 25.75% to $5.7 million in 2024, then tumbled by 45.28% to $3.1 million in 2025, then surged by 71.23% to $5.4 million in 2026.
• The last three Payables figures came in at $5.4 million (Q1 2026), $3.1 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.